Sylvie D. Freeman

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis.

Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis.

Journal: Blood advances

Published: May 13, 2026

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Journal: Blood

Published: December 05, 2025

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Journal: Blood

Published: September 16, 2025

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

Journal: Blood

Published: September 16, 2025

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Journal: Blood

Published: July 28, 2025

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

Journal: Blood

Published: July 28, 2025

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Journal: Blood advances

Published: May 23, 2025

Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel.

Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel.

Journal: Haematologica

Published: May 15, 2025

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Journal: Blood

Published: April 18, 2025

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.

Journal: Cancer

Published: March 25, 2025

Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML.

Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 28, 2025

A revised prognostic model for patients with acute myeloid leukemia and first relapse.

A revised prognostic model for patients with acute myeloid leukemia and first relapse.

Journal: Blood advances

Published: January 06, 2025

Showing 1-12 of 74

Last Updated: 09/26/2026